Latest News

Robitussin Cough Syrup Recalled Nationwide Due to Fungus Concerns


 

Some Robitussin cough syrup products are being recalled nationwide due to potentially deadly microbial contamination.

The company that makes Robitussin syrups did not specify which microorganisms may be in the products. The recall announcement from the global consumer health products company Haleon stated that the contamination could lead to fungal infections or the presence of fungi or yeasts in a person’s blood. So far, the company has not received any reports of people being sickened by the recalled products.

The recall applies to bottles of Robitussin Honey CF Max Day and Robitussin Honey CF Max Nighttime. Both varieties are for adults. Affected products were sold nationwide and have specific lot numbers printed at the bottom of the back of the bottles. Consumers can view the lot numbers on the FDA’s recall webpage.

People with weakened immune systems have a higher risk of life-threatening health problems due to the cough syrup, the company warned.

“In non-immunocompromised consumers, the population most likely to use the product, life-threatening infections are not likely to occur,” the recall notice from Haleon stated. “However, the occurrence of an infection that may necessitate medical intervention cannot be completely ruled out.”

People who have affected products should stop using them immediately. The company asked that anyone with the products email Haleon at mystory.us@haleon.com, or call the company at 800-245-1040 Monday through Friday from 8 a.m. to 6 p.m. Eastern time.

A version of this article appeared on WebMD.com.

Recommended Reading

Marijuana use dramatically increases risk of heart problems, stroke
Clinician Reviews
Diagnosing patients with sarcoidosis
Clinician Reviews
Revisiting the role of hydrocortisone, fludrocortisone in septic shock
Clinician Reviews
Intense exercise may lead to colds. A new study tells us why
Clinician Reviews
Chest pain with long COVID common but undertreated
Clinician Reviews
Pulmonary arterial hypertension: Promising results for investigational agents and catheter-based denervation
Clinician Reviews
New COVID variant JN.1 could disrupt holiday plans
Clinician Reviews
Catheter-directed strategy improves pulmonary artery occlusion
Clinician Reviews
High and Low Body Mass Indices Promote Respiratory Symptoms
Clinician Reviews
A Military Nurse Saves a Life After a Brutal Rollover Crash
Clinician Reviews